Watertown, United States
Larkspur Biosciences is a biotechnology startup established in 2020, based in the United States. The company's mission is to develop precision immunotherapies to combat cancer. Their approach is centered around addressing the unique ways tumors manipulate the immune system, with a focus on molecularly defined patient populations. The aim is to overcome the barriers that tumors exploit to evade the immune system.
Larkspur Biosciences is actively progressing their first-in-class programs to bolster immune responses in colorectal cancer and various other types of cancer. The company's LarkX platform, which is dedicated to target discovery, utilizes patient-derived data on tumor genetics and immune phenotypes to drive its pipeline, presenting opportunities to address multiple cancer types.
The recent milestone for Larkspur Biosciences was the $35.50M Series A investment received on 23 May 2023. The investment was made by Polaris Partners, 3E Bioventures Capital, and Takeda Ventures, reflecting confidence in the company's innovative approach to cancer treatment. With a dedicated team and a strong track record in drug discovery and development, Larkspur Biosciences aims to deliver groundbreaking medicines to address the significant unmet needs of cancer patients.
The company's commitment to fostering a culture that values joy, trust, and courage underscores its dedication to making a meaningful impact in the fight against cancer.
